Here are a bunch of little bites to satisfy your hunger for movie culture:
Vintage Image of the Day:
Following the back-to-back deaths of Carrie Fisher and Debbie Reynolds, many have shared the incredible photograph seen below. The New York Times shares the story behind it:
Footage from the new Alien: Covenant trailer has been repurposed for a retro version akin to the original Alien trailer (via Cinematic Montage Creators):
[embedded content]
Recreated Scene of the Day:
SPOILER: Mr. Sunday Movies animated the final Darth Vader sequence from Rogue One: A Star Wars Story in 16-bit video game style graphics:
[embedded content]
Musical Preview of the Day:
Here’s a tease of Emma Watson singing “Something There” in Disney’s live-action remake of Beauty and the Beast as heard through a new doll (via Heroic Hollywood):
A photo posted by Loot Crate (@lootcrate) on Dec 26, 2016 at 10:00am PST
Movie Pitch of the Day:
The movie described in this pitch for a script featuring 100 cliches starts out sounding a lot like Passengers (via Geek Tyrant):
[embedded content]
Year-End Recap of the Day:
Today’s look back at 2016 in film is from No Film School and is focused on the best cinematography of the year:
[embedded content]
Classic Trailer of the Day:
Today is the 10th anniversary of the U.S. release of Pan’s Labyrinth. Watch the original American trailer for Guillermo del Toro’s Oscar-winning classic below.
Ed Welburn, vice president of General Motors Global Design, stands with the Buick Riviera concept as it makes its North American debut at the North American International Auto Show in 2008 in Detroit. John F. Martin/Courtesy of General Motorshide caption
toggle caption
John F. Martin/Courtesy of General Motors
Car designers are a type. They stand out from the engineers, accountants and lawyers that populate the car business. By all accounts, Ed Welburn, General Motors’ first global head of design, is quiet, focused and congenial. This year, he retired after 44 years at GM.
“These are oversized individuals,” says Bill Pretzer, a curator with the Smithsonian’s National Museum of African American History and Culture. He’s referring to famed auto designers like Chuck Jordan or Harley Earl. “They have huge personalities and are in many ways grandiose, and Ed is exactly the opposite,” Pretzer adds.
Welburn’s passion for cars started early. He didn’t come out of the womb thinking about cars, but by age 3 he was drawing them.
And before he could properly tie his shoes, he was fixing bikes in the backyard. In 1959, when he was 8, Welburn’s parents took him to the Philadelphia Auto Show and changed his life.
When Ed Welburn saw a 1959 Cadillac Cyclone concept — think rocket ship on wheels — at an auto show in Philadelphia as an 8-year-old, he knew he wanted to design cars. Courtesy of General Motorshide caption
toggle caption
Courtesy of General Motors
“I saw that car, and that car took me from being crazy about cars to this is it — this is what I wanna do,” Welburn says. That car was the Cadillac Cyclone, a concept car. Chuck Jordan, the famed promoter of the fin at Cadillac, was just arriving on the scene. When you look at the Cyclone now, it’s easy to understand how it would have captured a young boy’s imagination: It’s a rocket ship on wheels.
It wasn’t just that Welburn wanted to design cars. He wanted to design crazy new-age cars like the Cyclone. “It was an emotional connection,” he says. “And that’s what I strive for in every design that we develop. … That car connected with me,” he says wistfully, sitting in GM’s Burbank design studio, one of 10 around the globe that Welburn led for more than a decade.
“It was through car magazines that I found out where that car came from,” he says. At age 11, Welburn wrote a letter to GM Design. “I want to be a car designer when I grow up. What courses should I take? What do I need to do?” he wrote.
GM wrote back! The head of personnel sent the young man brochures to the top design schools. The automaker knew he was 11, but it seemed to take him seriously.
When he was in high school, still obsessed with cars and designing them, Welburn began to apply to design schools. But his youthful enthusiasm soon met the reality of being an ambitious smart black man in the 1960s.
“You make it through the first wave because your grade-point average was excellent and then you present your portfolio,” he says. “Design school after design school that was on that list from GM rejected me. And that was this big shock to my system.”
It’s important to understand that getting into a car design program is a direct pipeline to designing cars. Students are recruited in their freshman year. An internship with a car company often turns into a job.
Bill Pretzer with the Smithsonian says that Welburn’s family was in many ways typical of their time, determined to move up the economic ladder. “There’s a phrase in many African-American communities called ‘making a way out of no way.’ … If confronted with obstacles you still find a way. And this was a family that consistently found a way to make a way out of no way.”
The Welburn family’s way was through Howard University. Welburn was accepted into the art school at the historically black college at a powerful moment at Howard and in the country. He was a sculpture student studying under the great Harlem renaissance painter Lois Jones.
The university already had a design program and a sculpture program. It created a car design curriculum for Welburn from within the art school. He says his unconventional school would become a benefit.
“You could hear Roberta Flack in the music studio studying. You go down the hall … and there’s Debbie Allen, Phylicia Rashad there studying. We were all students together. That was an incredible environment in which to grow,” he says. It was that environment in art school that burnished his skills as an artist and placed him firmly in the black art world.
Eventually, Welburn would get an internship in GM’s sculpture studio. It was a summer program and by then he was hooked. Welburn says he learned as much in those 10 weeks on the job as he would in two years in the classroom At the end of that summer, Welburn says he heard from his boss: “He said, ‘You just go back, finish your senior year at Howard. We wanna hire you.’ “
So Welburn went back, finished his senior year and turned the internship into a career that would last 44 years and make him the highest ranking African-American in the history of the auto industry. His first project was to design the tail lamp for the Pontiac Grand Ville.
Ed Welburn was an intern at General Motors Design in 1971. He began his GM career the following year as an associate designer assigned to the Advanced Design Studios. Courtesy of General Motorshide caption
toggle caption
Courtesy of General Motors
“The guy has impeccable design sense and judgement,” says Stewart Reed, a renowned car designer and chairman of Art Center Transportation Design. He says you can tell a Welburn design: “You know when it comes to seeing a car’s posture and proportion, and then right down to the details that support the overall character of the car.”
Welburn says it was during those early years that he came up with his chief principle — that design and engineer should be one. He came up with his philosophy:
You have got to have a very clear vision of what you’re doing.
You have to have great collaboration across the company in what you’re doing.
There must be a collaboration between design and engineering.
Most importantly: “I don’t design the cars for me. … You design it for your customers. You’ve got to listen to them, spend time with them.”
It was that kind of thinking that led Welburn to hit after hit in the car world.
In 1996, Ed Welburn began a two-year assignment at Saturn. That led to an assignment in Germany, where he worked on future GM global design programs. Courtesy of General Motorshide caption
toggle caption
Courtesy of General Motors
He led the design team at Saturn. He was instrumental in designing or redesigning vehicles such as the Volt, the Hummer, the Escalade, the Corvette and many others.
Reed says Welburn’s job and his impact is less about picking this fin or that color. He likens Welburn to the great conductors. He set a standard and allowed his designers freedom, Reed says.
“The guy that you want responsible for the orchestra should be an artist, a musician,” Reed says. “And maybe they’re not good at every instrument. Maybe they’re a pianist or something, but they have a sense of how all these talents work together for a result.”
Reed says that because of the dignity and the skill with which Welburn worked in the corporate environment, “he has placed design on a much higher plane. It’s respected more. Designers at GM are doing well. They’re respected, they’re getting great results. They’re supported by the rest of the corporation because of leadership.” All that, Reed says, is still somewhat unusual in the car business.
Glenda Gill is an automotive consultant, who spent years as a consultant and lobbied the industry for more diversity. She was executive director of the Rainbow PUSH Automotive Project.
“We always state about being twice as good. Just know that [Welburn] was three times as good in his industry, and well respected, and was a mentor to many,” she says. As the head of design, Gill says, Welburn reshaped car design but was also a beacon for African-Americans throughout the industry.
More importantly, she says, by his example he taught the car business a lesson. She says somebody decide to take a chance on him, “and guess what? They won.” She says Welburn is the embodiment of what diversity can bring to a company: “He’s great, he’s passed every test, we’re going to [pick] him based upon his merit and see what he does, and he did it.”
Going into the last weekend of the NFL’s regular season, the Tampa Bay Buccaneers have the longest of odds to make the playoffs. Seven different things need to go right for them.
(SOUNDBITE OF SAM SPENCE SONG, “THE EQUALIZER”)
ROBERT SIEGEL, HOST:
We’re heading into the last weekend of the NFL’s regular season, and there’s just one wildcard playoff spot still up for grabs. The Tampa Bay Buccaneers are still mathematically eligible.
ARI SHAPIRO, HOST:
Technically, but to say they’re longshots is putting it mildly. Seven different things need to go their way on Sunday if they’re going to make it to the postseason.
SIEGEL: First of all, Tampa needs to beat the Carolina Panthers – fair enough. That’s within their control.
SHAPIRO: Then it gets ridiculous. The Bucs need to sit back and pray that Green Bay and Houston and Jacksonville and Philadelphia and Seattle all lose their games.
SIEGEL: And amazingly, that’s not all. Washington and the New York Giants need to tie at the end of their game. No one can win. No one can lose. They must tie, which almost never happens in the NFL these days.
SHAPIRO: Still, mathematically, there is a chance. Given the long odds, the Bucs might have a few extra fans watching this weekend, folks who love rooting for the ultimate underdog and perhaps a few mathematicians as well.
NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.
Diseased brain tissue from an Alzheimer’s patient showing amyloid plaques (in blue) located in the gray matter of the brain. Dr Cecil H Fox/Science Source/Getty Imageshide caption
toggle caption
Dr Cecil H Fox/Science Source/Getty Images
In a disappointment to Alzheimer’s patients and researchers, drugmaker Eli Lilly said in late November that a clinical trial of solanezumab, an experimental medication to treat the degenerative neurological condition, had failed.
The company has pressed on with tests of solanezumab, despite mixed results in earlier studies. The latest test, involving more than 2,000 patients, found the drug didn’t significantly slow cognitive decline in patients with mild dementia from Alzheimer’s.
The sad refrain is a familiar one, unfortunately.
Solanezumab is just the latest casualty in a decades-long parade of disappointing dementia drug trials. But the frustration brought by this particular failure could signal a shift in Alzheimer’s research — a shift away from targeting accumulations of so-called amyloid protein in the brain, long considered by many in the field to be the crux of Alzheimer’s pathology.
Ever since Dr. George G. Glenner’s 1984 discovery that amyloid is the main component of the plaques that riddle the Alzheimer’s-afflicted brain, it has been assumed that the protein somehow contributes to the disorder — that it jams up cellular machinery, rendering neurons unable to effectively communicate, to form new memories, to remember where the keys are.
Like many other failed medications for symptomatic Alzheimer’s, solanezumab works by attacking amyloid in the brain.
So in light of the new findings, is it finally time to let the amyloid theory go? The answer isn’t clear.
“The low magnitude of effects would lend support to the idea that it might be time to move on from amyloid,” says Weill Cornell Medical College neurologist Dr. Richard Isaacson, who wasn’t involved in the solanezumab study. “Yet though the study failed overall, there were improvements in cognition and function in treated patients.”
He points out that perhaps the tested dose wasn’t high enough or that the patients’ disease was too advanced to respond. By the time symptoms of Alzheimer’s arise, the brain is already speckled with amyloid. Two other ongoing trials should confirm whether solanezumab is more effective in patients at risk for Alzheimer’s, but who have not yet developed symptoms, he says.
Solanezumab, an antibody, works by attacking amyloid floating in cerebrospinal fluid. A different type of investigational medication, so-called BACE inhibitors, prevent amyloid formation in the first place, by neutralizing an enzyme that cuts away amyloid from a larger protein. Biogen’s aducanumab, another experimental drug that’s far along in clinical testing, binds to and clears amyloid that is already ensnared in plaques.
Earlier this year the FDA granted aducanumab fast-track status after results from a small, early-stage study suggested that it reduces amyloid plaques and slows cognitive decline in people with very early stage disease. Those people did have amyloid deposits visible with positron emission tomography imaging. At the Clinical Trials on Alzheimer’s Disease and Dementia meeting in San Diego in early December, follow-up data were presented that confirmed cognitive improvement out to two years of treatment.
“The good news is that there are a number of trials in progress with different anti-amyloid drugs in asymptomatic subjects; and that one failed drug doesn’t mean that another won’t have an effect,” says Dr. James Burke, professor of medicine and psychiatry at Duke University’s Alzheimer’s Disease Research Center. “These trials also suggest that the best chance for a significant effect on cognition is likely to be treating asymptomatic people with amyloid deposits on imaging.”
Yet, Burke adds, if these trials don’t show a significant clinical benefit, the focus on amyloid will likely end.
In any event, Weill’s Isaacson feels that researchers should be looking to other options. “I’ve never been a firm believer in the amyloid hypothesis being the be-all and end-all as to the cause of Alzheimer’s,” says Isaacson. “I think it’s much more complicated and there are probably many roads leading to the disease.”
Fluorescent deconvolution micrograph of cultured glial cells expressing tau protein (in red). Glial cells are nervous system cells that provide structural support and protection for neurons (nerve cells). Accumulation of tau in brain tissue is linked with a number of neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. Roger J. Bick, Kha Dinh/Mya C. Schiess / UT-Houston Medical/Science Sourcehide caption
One such road might be to target the tau protein, which also accumulates in tangles inside the Alzheimer’s-hindered brain. Another involves treating the inflammation that occurs with dementia, as the immune system attempts to clear clustered amyloid. Even simpler are dietary interventions. Mediterranean-like diets high in omega-3 fatty acids show particular promise in slowing cognitive decline.
As in so many other disorders, fully understanding Alzheimer’s disease might ultimately entail figuring out how our bodies interact with the trillions of microbes living in our guts, or our “microbiota.” Research in animals and humans suggest that certain combinations of these organisms may rev up the immune system in ways that contribute to dementia. A study published in July in Scientific Reports found that a long course of antibiotic treatment to alter gut flora in dementia-prone mice reduced the number and size of amyloid plaques in the brain.
Whether it’s antibiotics, probiotics or vaccines, the list of potential Alzheimer’s treatments being considered goes on.
“The bottom line is we need to take more shots on goal,” says Isaacson. “The next frontier is recognizing that there probably isn’t a one-size-fits-all approach, and that using targeted therapies based on a person’s own biology and genetics will bring the most benefit. The future of Alzheimer’s therapeutics is in precision medicine.”
Bret Stetka is a writer based in New York and an editorial director atMedscape. His work has appeared in Wired, Scientific American and on The Atlantic.com. He graduated from University of Virginia School of Medicine in 2005. He’s also on Twitter:@BretStetka.
Legendary actress Debbie Reynolds has died, according to multiple media reports, one day after her daughter Carrie Fisher unexpectedly passed away. She was 84.
Her son, Todd Fisher, told Variety: “She wanted to be with Carrie.”
Born in El Paso, Texas, Reynolds and her family moved to California when she was 8 years old. After she became an actress and landed a few supporting roles, her big break came in the immortal musical Singin’ in the Rain. She displayed a bright comic touch and held her own as a singer and dancer against Gene Kelly and Donald O’Connor.
[embedded content]
Reynolds soon soared into movie stardom, proving especially popular in light comedies like Susan Slept Here and Tammy and the Bachelor. But she could also handle roles with greater depth, as in the comic musical drama The Unsinkable Molly Brown. She earned an Academy Award nomination as best actress for that performance.
[embedded content]
As her movie career waned, the talented singer focused on nightclub performances and stage productions. In the 1970s, she became a noted collector of movie memorabilia and got more involved in various business ventures.
She also continued her career as an actress, appearing on television and occasionally in movies, such as Heaven and Earth, In and Out and One for the Money. Probably her most notable late role came in Albert Brooks’ wonderful Mother.
[embedded content]
Debbie Reynolds received the Jean Hersholt Humanitarian Award at the 88th annual Academy Awards, presented by Meryl Streep in a speech that summarizes her fabulous career.